Background: Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs),
Introduction
Both acetaminophen and NSAIDs (nonsteroidal anti-inflammatory drugs) are commonly used to relieve pain and lower fever, but acetaminophen does not relieve inflammation due to rheumatoid arthritis (1) and is not traditionally considered an NSAID. However, both studies of osteoarthritis and dental surgery, and studies using rodent models indicate that acetaminophen can have anti-inflammatory effects (2) . In contrast to the large number of studies of NSAID use and prostate cancer, relatively few studies have examined acetaminophen use (5) (6) (7) (8) (9) . In the largest study to date, an analysis of a prescription database from the United Kingdom including 2,182 prostate cancer cases, overall use of acetaminophen was not associated with risk of prostate cancer, but long-term use ( > 4 years) was associated with substantially lower risk (OR = 0.50, 95% CI 0.38-0.65) (6) .
Four other studies reported no association between acetaminophen use and risk of prostate cancer (5, (7) (8) (9) . However, only two of these examined long-term use (7, 9) , and neither specifically examined use that was both long-term and regular.
We examined the association between acetaminophen use and risk of prostate cancer among men in the Cancer Prevention Study-II (CPS-II) Nutrition Cohort, focusing specifically on long-term regular use. The CPS-II Nutrition Cohort is well-suited to examine this association due to the availability of a large number of prostate cancer cases and regularly updated information on acetaminophen use.
Methods

Study Cohort
Men in this analysis were drawn from the 86,402 male participants in the CPS-II Nutrition Cohort, a prospective study of cancer incidence in the United States established in 1992 and This analysis excluded men with a history of prostate cancer at enrollment (N=3,729), with missing or incomplete information on acetaminophen use at enrollment (N= 994), who were lost to follow-up (alive at the time of the first follow-up questionnaire in 1997, but did not complete the 1997 or any subsequent follow-up questionnaire, N = 2,958), or who had missing information on year of prostate cancer diagnosis (N=19). A total of 889 men reported a prostate cancer diagnosis that could not be verified and therefore were not counted as cases. Of these, we excluded men who reported a prostate cancer diagnosis during the first follow-up interval (N=217), but allowed the remaining 672 men who reported a prostate cancer during later followup intervals to contribute person-time until the start of the follow-up interval in which they reported a prostate cancer diagnosis. A total of 78,485 men remained for analysis.
Ascertainment of Cancer Cases
Of the 8,092 prostate cancer cases included in this analysis, 7,854 were initially identified by self-report on the follow-up questionnaires and were subsequently verified by obtaining medical records, or through linkage with state cancer registries when complete medical records could not be obtained (10) . Ascertainment of cancer by self-report is estimated to have a sensitivity of 93% in the Nutrition Cohort (11) . An additional 238 cases of cancer were identified through linkage with the National Death Index (12), of which 193 were verified through subsequent linkage with state cancer registries. Sixty-three men diagnosed with T1a prostate cancers were censored at their diagnosis date rather than being counted as cases because Gleason score, and/or histologic grade (N=343) were censored from analyses of aggressive and non-aggressive cancer, but were included as cases in analyses of overall prostate cancer. Cox proportional hazards regression models (14) were used to estimate relative risks (RR) and 95% confidence intervals (CI) for incident prostate cancer. Follow-up time for Cox models began on the date of completion of the 1992 questionnaire. All models were adjusted for age, race, education, body mass index (BMI), diabetes, use of nonsteroidal antiinflammatory drugs (NSAIDs, including aspirin), and history of PSA testing. Age was adjusted for using the stratified Cox procedure (15) with one year strata. All other covariates were modeled using the categories shown in Table 1 . History of PSA testing, NSAID use, and diabetes were modeled as time-dependent variables, using updated information from follow-up questionnaires. All other covariates were modeled based on status in 1992.
Assessment of Acetaminophen Use
Because acetaminophen may inhibit inflammation, we examined if the association between long-term regular acetaminophen use and prostate cancer was modified by use of NSAIDs and BMI (which is associated with systemic inflammation (16, 17) 
acetaminophen use for > 5 years, and NSAID use (time-dependent continuous variable for pills per month) and BMI (continuous). Table 1 Specific information on dose of acetaminophen was not available. However, among long-term regular users in 1997, the median number of pills per day was 2.0. Only 14% of long-term regular users in 1997 reported use of more than 4 pills per day. Given that an extra-strength tablet available in the United States typically contains 500 mg of acetaminophen, few long-term regular users in this study are likely to have regularly used more than 2,000 mg/day (half of the maximum recommended daily dose of 4,000 mg).
Results
Current regular use for < 5 years was not associated with prostate cancer risk (Table 2 ). 
Discussion
In this large prospective study, regular use of acetaminophen (> 30 pills/month) for 5 or more years was associated with considerably lower risk of both aggressive and overall prostate cancer. Shorter-term use of acetaminophen was not associated with risk of prostate cancer.
To our knowledge, five other epidemiologic studies have examined the association between acetaminophen use and risk of prostate cancer (5-9). Our results are consistent with those of the largest of these studies, an analysis of computerized prescription data from the United Kingdom (UK) that included 2,182 prostate cancer cases (6) . In that analysis, total duration of acetaminophen use during a study period of up to 7 years was calculated by summing the intended duration of all prescriptions; use for < 1 year was associated with slightly higher risk (OR = 1.14, 95% CI 1.00-1.31), attributed to reverse causation, use for 1-2 years was associated with lower risk (OR = 0.67, 95% CI 0.49-0.92), no clear association was seen with use of 2-4 years (OR = 0.87, 95% CI 0.66-1.15) and use for > 4 years was associated with considerably lower risk (OR = 0.50, 95% CI 0.38-0.65). Four other studies reported no association between acetaminophen use and prostate cancer risk (5, (7) (8) (9) . However, none of these studies examined acetaminophen use that was both long-term and regular. In a U.S. 
prostate cancer cases (7), there was no apparent association between acetaminophen use for > 5 years and prostate cancer risk (OR = 0.88, 95% CI 0.34-2.33) but statistical power was limited. Two additional studies, a Danish pharmacy database analysis (5), and a case-control study in the UK (8), did not examine either long-term or regular use. In the Danish analysis (5), acetaminophen use was defined as having received at least one prescription for acetaminophen. In the UK case-control study, acetaminophen use was defined as any reported current use (8) . Overall, results of our study, together with those of other studies, suggest that if there is any association between acetaminophen use and prostate cancer it is likely to be limited to long-term regular use.
While epidemiologic evidence remains limited, it is biologically plausible that acetaminophen use could reduce prostate cancer risk by inhibiting chronic inflammation, which is hypothesized to increase risk of prostate cancer (18) . Acetaminophen, like NSAIDs, may act by inhibiting the cyclooxygenase-2 (COX-2) enzyme, an important mediator of inflammation (1, 19, 20) . One recent study reported that a standard clinical dose of acetaminophen reduced COX-2 activity in whole blood as much as a standard clinical dose of the selective COX-2 inhibitor celecoxib (21) . In addition, three recent studies reported an inverse association between acetaminophen use and serum prostate specific antigen (PSA) levels among men without prostate cancer (7, 8, 22) . The largest of these studies included 263 acetaminophen users and found acetaminophen use to be associated with a statistically significant 9% reduction in mean serum PSA level (8) . In each study, acetaminophen use was associated with a larger reduction in PSA level than was NSAID use. Because serum PSA levels can reflect prostatic inflammation (23, 24) , these studies provide indirect evidence that acetaminophen may inhibit inflammation in the prostate.
It is important to consider the possible effect of acetaminophen on serum PSA levels when interpreting our results. If long-term regular acetaminophen use reduced serum PSA levels in our study population, there are at least two possible interpretations of our results. First, acetaminophen use might have had biological effects on the prostate (e.g. reduced inflammation) that both reduced serum PSA and inhibited prostate carcinogenesis.
Alternatively, acetaminophen use might have reduced serum PSA but had no biological effect on prostate carcinogenesis. In this case, the lower risk of prostate cancer diagnosis among long-term acetaminophen users in our study could have been due solely to a reduction in the sensitivity of PSA testing. However, a reduction in PSA sensitivity due to acetaminophen use would be expected to delay prostate cancer diagnosis, and therefore result in a lower risk of non-aggressive prostate cancer, but not necessarily in a lower risk of aggressive prostate cancer. In our study, the lower risk associated with long-term regular acetaminophen use was, if anything, more apparent for aggressive prostate cancer than for non-aggressive prostate cancer.
A limitation of our study is that the prevalence of long-term regular acetaminophen use was low, resulting in relatively few cases with this exposure and limiting the precision of our risk estimate. Also, no information was available on dose per tablet of acetaminophen. In addition, as in all observational studies of this topic, confounding by factors associated with both acetaminophen use and prostate cancer risk cannot be ruled out. However, adjustment for measured prostate cancer risk factors had negligible influence on results. We are not aware of unmeasured factors that are strongly associated with both acetaminophen use and prostate cancer risk. Finally, the validity of self-reported acetaminophen use is unknown and there was undoubtedly some error in reporting. However, errors in reporting of acetaminophen use are unlikely to differ based on outcome, and therefore are unlikely to explain the association between long-term regular acetaminophen use and lower risk of prostate cancer.
Important strengths of our study include its large size and prospective design and the ability to identify long-term regular users of acetaminophen based on repeated questionnaires.
With the exception of the pharmacy database analysis from the UK (6) previous studies have not specifically examined the association between long-term regular use of acetaminophen and risk of prostate cancer.
In summary, long-term regular acetaminophen use was associated with approximately 38% lower risk of prostate cancer in this large prospective study. While this result is intriguing, it should be noted that acetaminophen use can have adverse effects including liver damage, although it is considered relatively safe at recommended doses (25) (26) (27) ). Further research is needed both to clarify the association between long-term regular acetaminophen use and prostate cancer and to investigate potential biological mechanisms through which acetaminophen may inhibit prostate carcinogenesis. 
